Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88

R. Daifuku, K. Haenftling, J. Young, E. S. Groves, C. Turrell, Frederick J Meyers

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.

Original languageEnglish (US)
Pages (from-to)2349-2351
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume36
Issue number10
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88'. Together they form a unique fingerprint.

  • Cite this

    Daifuku, R., Haenftling, K., Young, J., Groves, E. S., Turrell, C., & Meyers, F. J. (1992). Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. Antimicrobial Agents and Chemotherapy, 36(10), 2349-2351.